Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Jan Beyer

Showing results (201-210 of 225) with videos related to

Pageof 23
Sort By:
Blood Advances|April 11, 2018
Risk of recurrent venous thromboembolism according to baseline risk factor profilesMartin H Prins, Anthonie W A Lensing, Paolo Prandoni, et al.
Stroke|May 7, 2026
Predictors of Hematoma Expansion and Response to Andexanet in Patients With Intracerebral Hemorrhage: Secondary Analyses of the ANNEXA-I Randomized Clinical TrialAshkan Shoamanesh, Stuart J Connolly, Andrew M Demchuk, et al.
Blood Advances|April 19, 2022
Rivaroxaban for the treatment of noncirrhotic splanchnic vein thrombosis: an interventional prospective cohort studyWalter Ageno, Jan Beyer Westendorf, Laura Contino, et al.
The New England Journal of Medicine|March 21, 2017
Rivaroxaban or Aspirin for Extended Treatment of Venous ThromboembolismJeffrey I Weitz, Anthonie W A Lensing, Martin H Prins, et al.
Journal of the American College of Cardiology|March 25, 2017
Impact of Thrombolytic Therapy on the Long-Term Outcome of Intermediate-Risk Pulmonary EmbolismStavros V Konstantinides, Eric Vicaut, Thierry Danays, et al.
JAMA Internal Medicine|July 14, 2015
Long-term Clinical Outcomes of Splanchnic Vein Thrombosis: Results of an International RegistryWalter Ageno, Nicoletta Riva, Sam Schulman, et al.
Thrombosis and Haemostasis|August 15, 2015
Edoxaban for treatment of venous thromboembolism in patients with cancer. Rationale and design of the Hokusai VTE-cancer studyNick van Es, Marcello Di Nisio, Suzanne M Bleker, et al.
Thrombosis and Haemostasis|July 31, 2018
Clinical Impact of Bleeding in Cancer-Associated Venous Thromboembolism: Results from the Hokusai VTE Cancer StudyNoémie Kraaijpoel, Marcello Di Nisio, Frits I Mulder, et al.
The New England Journal of Medicine|August 31, 2016
Andexanet Alfa for Acute Major Bleeding Associated with Factor Xa InhibitorsStuart J Connolly, Truman J Milling, John W Eikelboom, et al.
The Lancet. Haematology|August 18, 2019
Bodyweight-adjusted rivaroxaban for children with venous thromboembolism (EINSTEIN-Jr): results from three multicentre, single-arm, phase 2 studiesPaul Monagle, Anthonie W A Lensing, Kirstin Thelen, et al.
Pageof 23

Showing results (201-210 of 225) with videos related to

Sort By:
Pageof 23
Blood Advances|April 11, 2018
Risk of recurrent venous thromboembolism according to baseline risk factor profilesMartin H Prins, Anthonie W A Lensing, Paolo Prandoni, et al.
Stroke|May 7, 2026
Predictors of Hematoma Expansion and Response to Andexanet in Patients With Intracerebral Hemorrhage: Secondary Analyses of the ANNEXA-I Randomized Clinical TrialAshkan Shoamanesh, Stuart J Connolly, Andrew M Demchuk, et al.
Blood Advances|April 19, 2022
Rivaroxaban for the treatment of noncirrhotic splanchnic vein thrombosis: an interventional prospective cohort studyWalter Ageno, Jan Beyer Westendorf, Laura Contino, et al.
The New England Journal of Medicine|March 21, 2017
Rivaroxaban or Aspirin for Extended Treatment of Venous ThromboembolismJeffrey I Weitz, Anthonie W A Lensing, Martin H Prins, et al.
Journal of the American College of Cardiology|March 25, 2017
Impact of Thrombolytic Therapy on the Long-Term Outcome of Intermediate-Risk Pulmonary EmbolismStavros V Konstantinides, Eric Vicaut, Thierry Danays, et al.
JAMA Internal Medicine|July 14, 2015
Long-term Clinical Outcomes of Splanchnic Vein Thrombosis: Results of an International RegistryWalter Ageno, Nicoletta Riva, Sam Schulman, et al.
Thrombosis and Haemostasis|August 15, 2015
Edoxaban for treatment of venous thromboembolism in patients with cancer. Rationale and design of the Hokusai VTE-cancer studyNick van Es, Marcello Di Nisio, Suzanne M Bleker, et al.
Thrombosis and Haemostasis|July 31, 2018
Clinical Impact of Bleeding in Cancer-Associated Venous Thromboembolism: Results from the Hokusai VTE Cancer StudyNoémie Kraaijpoel, Marcello Di Nisio, Frits I Mulder, et al.
The New England Journal of Medicine|August 31, 2016
Andexanet Alfa for Acute Major Bleeding Associated with Factor Xa InhibitorsStuart J Connolly, Truman J Milling, John W Eikelboom, et al.
The Lancet. Haematology|August 18, 2019
Bodyweight-adjusted rivaroxaban for children with venous thromboembolism (EINSTEIN-Jr): results from three multicentre, single-arm, phase 2 studiesPaul Monagle, Anthonie W A Lensing, Kirstin Thelen, et al.
Pageof 23